(Q22252957)

7 February 2023

11

Keith Hawton

Keith

Hawton

1 reference

7 February 2023

2

Caroline Caddy

Caroline

Caddy

1 reference

7 February 2023

Tayla L McCloud

1

Tayla L

McCloud

1 reference

7 February 2023

Janina Jochim

3

Janina

Jochim

1 reference

7 February 2023

Jennifer M Rendell

4

Jennifer M

Rendell

1 reference

7 February 2023

Peter R Diamond

5

Peter R

Diamond

1 reference

7 February 2023

Claire Shuttleworth

6

Claire

Shuttleworth

1 reference

7 February 2023

Daniel Brett

7

Daniel

Brett

1 reference

7 February 2023

Ben H Amit

8

Ben H

Amit

1 reference

7 February 2023

Rupert McShane

9

Rupert

McShane

1 reference

7 February 2023

Layla Hamadi

10

Layla

Hamadi

1 reference

Cochrane Database of Systematic Reviews

7 February 2023

language of work or name

English

0 references

publication date

29 September 2015

0 references

published in

0 references

issue

9

0 references

page(s)

CD011611

0 references

cites work

Early antidepressant effect of memantine during augmentation of lamotrigine inadequate response in bipolar depression: a double-blind, randomized, placebo-controlled trial

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

A randomized add-on trial of an N-methyl-D-aspartate antagonist in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Anti-anhedonic effect of ketamine and its neural correlates in treatment-resistant bipolar depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

The effects of add-on low-dose memantine on cytokine levels in bipolar II depression: a 12-week double-blind, randomized controlled trial.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Decreased glutamate/glutamine levels may mediate cytidine's efficacy in treating bipolar depression: a longitudinal proton magnetic resonance spectroscopy study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Replication of ketamine's antidepressant efficacy in bipolar depression: a randomized controlled add-on trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

N-acetyl cysteine for depressive symptoms in bipolar disorder--a double-blind randomized placebo-controlled trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Therapeutic effects of add-on low-dose dextromethorphan plus valproic acid in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

The DRD2/ANKK1 gene is associated with response to add-on dextromethorphan treatment in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Do the dissociative side effects of ketamine mediate its antidepressant effects?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Systemic illness moderates the impact of N-acetyl cysteine in bipolar disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

A randomized comparison of ketamine versus methohexital anesthesia in electroconvulsive therapy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Ketamine for depression: where do we go from here?

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Ketamine alters neural processing of facial emotion recognition in healthy men: an fMRI study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Antidepressant effects of AMPA and ketamine combination: role of hippocampal BDNF, synapsin, and mTOR

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Plasma concentrations of excitatory amino acids, serine, glycine, taurine and histidine in major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Ketamine and other glutamate receptor modulators for depression in adults

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision (DSM-IV-TR)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

21 January 2018

2 references

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

21 January 2018

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

7 January 2021

Antidepressants versus placebo for depression in primary care

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Grading quality of evidence and strength of recommendations

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

NMDA receptor blockade at rest triggers rapid behavioural antidepressant responses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Inflammatory mediators of cognitive impairment in bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

New approaches to antidepressant drug discovery: beyond monoamines

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Subgroup analyses in randomised controlled trials: quantifying the risks of false-positives and false-negatives

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Subgroup analyses in randomized trials: risks of subgroup-specific analyses; power and sample size for the interaction test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Antidepressant effects of ketamine: mechanisms underlying fast-acting novel antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Ketamine as the prototype glutamatergic antidepressant: pharmacodynamic actions, and a systematic review and meta-analysis of efficacy

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Comparative efficacy and acceptability of 12 new-generation antidepressants: a multiple-treatments meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Sertraline versus other antidepressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Citalopram versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Lithium in the prevention of suicide in mood disorders: updated systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Duloxetine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

The use of ketamine as an antidepressant: a systematic review and meta-analysis

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Ketamine and other potential glutamate antidepressants

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Bias in meta-analysis detected by a simple, graphical test

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Meta-analyses involving cross-over trials: methodological issues

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Diagnostic Criteria for Use in Psychiatric Research

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Can we individualize the 'number needed to treat'? An empirical study of summary effect measures in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Imputing missing standard deviations in meta-analyses can provide accurate results

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Association between unreported outcomes and effect size estimates in Cochrane meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Treatment of bipolar disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Hydroxyzine for generalised anxiety disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Interpreting treatment effects in randomised trials

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

A rating scale for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Measuring inconsistency in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

NMDA receptor hypofunction produces opposite effects on prefrontal cortex interneurons and pyramidal neurons

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Subdissociative dose ketamine produces a deficit in manipulation but not maintenance of the contents of working memory.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

The long-term natural history of the weekly symptomatic status of bipolar I disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

A prospective investigation of the natural history of the long-term weekly symptomatic status of bipolar II disorder.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Synaptic mechanisms underlying rapid antidepressant action of ketamine

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Assessment and management of bipolar disorder: summary of updated NICE guidance.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

GABA and glutamate systems as therapeutic targets in depression and mood disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Characterization of treatment resistant depression episodes in a cohort of patients from a US commercial claims database

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Fluoxetine versus other types of pharmacotherapy for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Ketamine for treatment-resistant unipolar depression: current evidence

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Prevalence and correlates of bipolar spectrum disorder in the world mental health survey initiative

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

A New Depression Scale Designed to be Sensitive to Change

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Consequences of chronic ketamine self-administration upon neurocognitive function and psychological wellbeing: a 1-year longitudinal study

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Differentiating moderate and severe depression using the Montgomery-Asberg depression rating scale (MADRS).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Global, regional, and national incidence and mortality for HIV, tuberculosis, and malaria during 1990-2013: a systematic analysis for the Global Burden of Disease Study 2013.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

A review of ketamine in affective disorders: current evidence of clinical efficacy, limitations of use and pre-clinical evidence on proposed mechanisms of action

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Glutamate receptor antagonists as fast-acting therapeutic alternatives for the treatment of depression: ketamine and other compounds.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Family history of alcohol dependence and initial antidepressant response to an N-methyl-D-aspartate antagonist

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Paroxetine versus other anti-depressive agents for depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Ketamine: an update on the first twenty-five years of clinical experience

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

The Neurobiology of the Switch Process in Bipolar Disorder

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Research diagnostic criteria: rationale and reliability

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Publication and related bias in meta-analysis: power of statistical tests and prevalence in the literature

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Symptom profiles of depression among general medical service users compared with specialty mental health service users

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Comparative efficacy and acceptability of drug treatments for bipolar depression: a multiple-treatments meta-analysis.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Systematic review of lamotrigine augmentation of treatment resistant unipolar depression (TRD).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Metabolic hyperfrontality and psychopathology in the ketamine model of psychosis using positron emission tomography (PET) and [18F]fluorodeoxyglucose (FDG).

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Rapid-onset antidepressant efficacy of glutamatergic system modulators: the neural plasticity hypothesis of depression.

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

The MOS 36-ltem Short-Form Health Survey (SF-36)

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Health of the Nation Outcome Scales (HoNOS). Research and development

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

A randomized trial of an N-methyl-D-aspartate antagonist in treatment-resistant major depression

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Lamotrigine in the treatment of unipolar depression with and without comorbidities: a literature review

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

Imputing response rates from means and standard deviations in meta-analyses

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

A systematic review and meta-analysis of randomized, double-blind, placebo-controlled trials of ketamine in the rapid treatment of major depressive episodes

21 January 2018

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

7 January 2021

Induction of Mania With Serotonin Reuptake Inhibitors

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

7 January 2021

Evidence-based guidelines for interpretation of the Hamilton Rating Scale for Depression

1 reference

https://api.crossref.org/works/10.1002%2F14651858.CD011611.PUB2

7 January 2021

10.1002/14651858.CD011611.PUB2

Identifiers

DOI

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017

1 reference

Consolidated OpenCitations Corpus – April 2017